Heart failure & cardiomyopathies
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial
Authors' conclusion
Functional capacity can be impaired in young, healthy people with early stage HCM, despite New York Heart Association class I status and good HRQOL. Peak oxygen uptake was similarly decreased in subclinical HCM despite normal left ventricular wall thickness and excellent HRQOL. Valsartan improved physical pediatric quality of life scores but did not significantly impact CPET performance.
Study context
- Population
- VANISH participants with early stage sarcomeric or subclinical hypertrophic cardiomyopathy (HCM) who completed baseline and year 2 health-related quality of life (HRQOL) assessment and cardiopulmonary exercise testing (CPET)
- Participants
- 200 participants
- Comparison
- Early stage HCM vs Subclinical HCM
- Early stage HCMn = 166
- Subclinical HCMn = 34reference
- Primary endpoint
- HRQOL (pediatric quality of life inventory) and CPET performance
Primary result
As reported in the abstract
Early stage HCM
84.6
SD 10.6
Subclinical HCM
90.2
SD 9.8
P = 0.005
Further findings
| Outcome | Adjusted mean change | P value |
|---|---|---|
| Physical HRQOL (pediatric QOL score), early stage HCMValsartan vs Placebo · early stage HCM | +4.1 | P = 0.01 |
Baseline HRQOL (composite pediatric QOL score), early stage vs subclinical HCM
- HRQOL good in both cohorts, slightly better in subclinical HCM: 84.6±10.6 vs 90.2±9.8
- P = 0.005
Baseline mean % predicted peak oxygen uptake, both cohorts
- Mildly reduced functional status in both cohorts: 73±16 vs 78±12 mL/kg per minute
- P = 0.18
Correlates of HRQOL
- % predicted peak oxygen uptake and peak oxygen pulse correlated with HRQOL
CPET performance, early stage HCM
- Valsartan did not significantly impact CPET performance
Original publication
Summarised from the published abstract; every number is checked against it